



#84
DRAFT
5-6-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Docket No.: 2852-C

ANDERSON and GALIBERT

Confirmation No. 1630

Serial No: 09/688,459

Group Art Unit: 1646

Filed: October 13, 2000

Examiner: E. Lazar Wesley

For: ISOLATED DNA MOLECULE ENCODING RANK LIGAND

Commissioner for Patents
Washington, DC 20231

TECH CENTER 1600/2900

MAY 03 2002

RECEIVED

AMENDMENT AND RESPONSE

In response to the Office Action mailed December 18, 2001, please enter the following amendments into the application:

In the Specification:

At page 1, please delete the first paragraph following the heading "CROSS-REFERENCE TO RELATED PATENT APPLICATIONS" and substitute therefor the following paragraph:

B1
-- This application is a divisional of U.S. patent application 08/995,659, filed December 22, 1997, now U.S. patent 6,242,213, which claims benefit of priority under 35 U.S.C. §119(e) from USSN 60/064,671, filed October 14, 1997, USSN 60/077,181, filed March 7, 1997, and USSN 60/059,978, filed December 23, 1996. --

At pages 2-3, please delete the paragraph located at page 2, line 35 to page 3, line 3.

At page 3, please delete the paragraph at lines 4-8 and substitute therefor the following paragraph:

B2
-- Figure 2 demonstrates that RANKL enhances DC allo-stimulatory capacity. Allogeneic T cells were incubated with varying numbers of irradiated DC cultured as described in Example 13. The cultures were pulsed with [³H]-thymidine and the cells harvested onto glass fiber sheets for counting. Values represent the \pm standard deviation (SD) of triplicate cultures. --

At page 5, please delete in its entirety the paragraph at lines 10-19, which begins with "Soluble RANKL comprises a signal . . ." and substitute therefor the following paragraph:

05/02/2002 GGEBREGI 00000089 090089 09688459

05/02/2002 GGEBREGI 00000089 090089 09688459

04 FC:115 110.00 CH

01 FC:103 414.00 CH
02 FC:102 252.00 CH